Top Markets
#1 BCGame Coin BCGame Coin +5.93%
#2 Tornado Cash Tornado Cash +5.13%
#3 Fake World Assets Fake World Assets +3.87%
#4 StonkBroker StonkBroker +2.14%
#5 Osmosis Osmosis +2.14%
#6 AtomOne AtomOne +2.05%
#7 aPriori aPriori +1.76%
#8 Nockchain Nockchain +1.73%
#9 Ether.fi Ether.fi +1.62%
#10 BORA BORA +1.46%
Coin of the day
BCGame Coin BCGame Coin
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
LAVA Therapeutics N.V. LAVA Therapeutics N.V.

LAVA Therapeutics N.V.

LVTX
Rang in Aktien #25847
LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical... LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical development phase, dedicated to pioneering novel therapies for cancer. Utilizing its proprietary Gammabody platform, the company engineers innovative bispecific antibodies. These antibodies are specifically designed to engage and harness the potent and precise capabilities of gamma delta T cells, aiming to stimulate a robust anti-tumor immune response and ultimately enhance outcomes for individuals battling cancer. Key compounds in its clinical pipeline include LAVA-051, currently undergoing Phase 1/2a trials for various hematologic malignancies such as chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. Another front-runner, LAVA-1207, is also in Phase 1/2a clinical studies, targeting metastatic castration-resistant prostate cancer. Furthermore, LAVA Therapeutics is advancing additional Gammabody candidates: LAVA-1223, an investigational treatment for specific solid tumors that targets the epidermal growth factor receptor (EGFR), and preclinical assets LAVA-1266 and LAVA-1278, intended for a range of blood cancers. The company has also forged a research collaboration and licensing partnership with Janssen Biotech, Inc. This alliance focuses on the potential discovery and development of multi-specific antibody therapies aimed at a particular target across diverse therapeutic applications. Established in 2016, LAVA Therapeutics N.V. operates from its headquarters in Utrecht, the Netherlands.
Aktienkurs
$1.74
Zuletzt synchronisiert: 2025-11-28
Marktkapitalisierung
$45.77M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
13.73%
Land
NL
Handel LAVA Therapeutics N.V. (LVTX)

Kategorie

Healthcare
Gewinn für LAVA Therapeutics N.V. (LVTX)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von LAVA Therapeutics N.V. betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von LAVA Therapeutics N.V. von 2026 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
Nicht genügend Daten für die angegebenen Daten.
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US